I
Isamu Okamoto
Researcher at Kyushu University
Publications - 458
Citations - 25482
Isamu Okamoto is an academic researcher from Kyushu University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 64, co-authored 413 publications receiving 19982 citations. Previous affiliations of Isamu Okamoto include Emory University & Kumamoto University.
Papers
More filters
Journal ArticleDOI
Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study.
TL;DR: A quantitative investigation of the inter‐ and intra‐tumoural distribution of alectinib in different neuroblastoma xenograft models using matrix‐assisted laser desorption ionization MS imaging (MALDI‐MSI).
Journal ArticleDOI
Echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects
Isamu Okamoto,Kazuhiko Nakagawa +1 more
TL;DR: This review focuses on the biology and clinical features of, as well as diagnostic testing for, EML4‐ALK‐positive NSCLC, and current data on the efficacy and toxicity of crizotinib are examined.
Journal ArticleDOI
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Hibiki Udagawa,Hiroaki Akamatsu,Kentaro Tanaka,Masayuki Takeda,Shintaro Kanda,Keisuke Kirita,Shunsuke Teraoka,Kazuhiko Nakagawa,Yutaka Fujiwara,Ikuko Yasuda,Sumiko Okubo,Masayuki Shintani,Matthew P. Kosloski,Charity D. Scripture,Tomohide Tamura,Isamu Okamoto +15 more
TL;DR: The preliminary data support further exploration of Rova-T treatment in Japanese patients with SCLC in global studies and safety and pharmacokinetics exposures were similar to previous observations in non-Japanese populations.
Journal ArticleDOI
Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yuzo Yamamoto,Isamu Okamoto,Kohei Otsubo,Eiji Iwama,Naoki Hamada,Taishi Harada,Koichi Takayama,Yoichi Nakanishi +7 more
TL;DR: The first reported case of alectinib-induced severe interstitial lung disease (ILD) is reported, and doctors should be aware of the possibility of such a severe adverse event and should therefore carefully monitor patients treated with this drug.
Journal ArticleDOI
Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment.
Toyoshi Yanagihara,Kentaro Tanaka,Keiichi Ota,Eiji Kashiwagi,Ario Takeuchi,Katsunori Tatsugami,Masatoshi Eto,Yoichi Nakanishi,Isamu Okamoto +8 more